Compare RBCAA & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | PVLA |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1998 | 2013 |
| Metric | RBCAA | PVLA |
|---|---|---|
| Price | $91.21 | $125.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $231.25 |
| AVG Volume (30 Days) | 74.8K | ★ 194.5K |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | $42,810,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.20 | N/A |
| P/E Ratio | $119.76 | ★ N/A |
| Revenue Growth | 8.50 | ★ 65.28 |
| 52 Week Low | $63.97 | $68.96 |
| 52 Week High | $102.22 | $161.38 |
| Indicator | RBCAA | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 40.41 |
| Support Level | $88.88 | $119.42 |
| Resistance Level | $93.78 | $136.35 |
| Average True Range (ATR) | 2.00 | 6.96 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 47.75 | 33.19 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.